BNTX

BioNTech (BNTX)

About BioNTech (BNTX)

BioNTech SE operates as immunotherapy company, which engages therapies for cancer and other serious diseases. Its product pipeline include BNT162b2, BNT161, BNT164, FixVac, iNeST, RiboMabs, CAR-T Cells, TCRs and Next-Gen CP Immunomodulators. The company was founded by Christopher Huber, Oezlem Tuereci, and Ugur Sahin on June 2, 2008 and is headquartered in Mainz, Germany.

Details

Daily high

$107.59

Daily low

$105.80

Price at open

$107.29

52 Week High

$124.49

52 Week Low

$81.20

Market cap

25.6B

Dividend yield

0.00%

Volume

739,507

Avg. volume

1.1M

P/E ratio

-40.55

BioNTech News